Applications of (S)-4-N-Boc-Piperazine-2-Carboxylic Acid in Industrial Manufacturing

(S)-4-N-Boc-Piperazine-2-Carboxylic Acid serves as a critical chiral building block for pharmaceutical synthesis, enabling targeted applications across peptide drug development, small-molecule API production, and advanced research chemicals. As a manufacturer specializing in this material, we directly support downstream processes where controlled stereochemistry and reliable intermediates are essential for large-scale and cGMP-compliant operations.

1. Peptide Drug Active Pharmaceutical Ingredient Production

Many peptide-based therapeutics require precisely configured piperazine-containing residues to achieve bioactivity. This compound functions as a protected chiral amino acid for solid-phase peptide synthesis (SPPS), allowing for site-selective integration into drug candidates targeting neurological, metabolic, and infectious diseases. Pharmaceutical manufacturers rely on high-purity intermediates to meet batch consistency and regulatory requirements in clinical-stage and commercial-scale API synthesis.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• United States Pharmacopeia (USP) monographs for peptide APIs
• European Pharmacopoeia (Ph. Eur.) Chapter 2034 — Peptide APIs
• cGMP guidelines set by the FDA and EMA

Typical usage ratio

• 0.5–2 equivalents per protected amino acid unit, adjusted based on targeted peptide length and sequence complexity

Downstream process integration

• Introduced during the main chain elongation phase using Fmoc or Boc SPPS protocols after resin loading

Final product types

• Injectable peptide drugs for oncology and endocrinology
• Lyophilized therapeutic peptides for clinical trials
• Oral peptide tablets for emerging drug delivery systems

2. Intermediate for Central Nervous System (CNS) Small-Molecule Pharmaceuticals

Downstream pharmaceutical manufacturers embed the piperazine-2-carboxylic acid core as a scaffold in CNS-active compounds, particularly within piperaquine derivatives and antipsychotic or antidepressant drug candidates. The N-Boc protection enables selective deprotection and further functionalization without racemization, supporting efficient route scouting in process chemistry and final API scale-up.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• FDA 21 CFR Part 211 requirements for finished pharmaceuticals
• EU Guidelines on process validation for APIs

Typical usage ratio

• 0.8–1.2 molar equivalents per key intermediate, refined according to target scaffold substitution pattern

Downstream process integration

• Used in cyclization and amidation steps as a key intermediate following Boc deprotection, often under inert conditions

Final product types

• Antidepressant and antipsychotic bulk APIs
• Research-grade CNS-active reference standards
• CNS drug intermediate stocks for custom synthesis platforms

3. Raw Material for Chiral Ligand Synthesis in Asymmetric Catalysis

Chemical manufacturers involved in chiral catalyst production leverage this protected intermediate to construct ligands used in transition metal-catalyzed asymmetric reactions. Its controlled stereochemistry and amine protection simplify multi-step syntheses, where downstream applications include industrial catalysis of pharmaceutical, agrochemical, and specialty fine chemical products.

Industry compliance standards

• ISO 9001:2015 Quality Management Systems for fine chemical production
• REACH Registration, Evaluation, Authorisation and Restriction of Chemicals (EU)
• Responsible Care® chemical safety management

Typical usage ratio

• 0.7–1.5 molar equivalents per ligand backbone, varying according to catalyst architecture

Downstream process integration

• Introduced during ligand backbone formation, typically via condensation or reductive amination, followed by global deprotection as needed

Final product types

• Chiral phosphine or diamine ligands for transition metal catalysis
• Enantioselective catalyst kits supplied to pharma and agrochemical sectors
• Bulk chiral catalysts for industrial fine chemical manufacturing

4. Key Starting Material for Beta-Lactamase Inhibitor Synthesis

APIs intended for combination antibiotic treatments often require chiral piperazine building blocks to produce advanced beta-lactamase inhibitors, which extend the lifespan and effectiveness of cephalosporin and carbapenem drugs. The acid derivative’s N-Boc protection preserves configuration and prevents premature amine reactivity during multi-step synthesis and scale-up.

Industry compliance standards

• cGMP: WHO TRS 986 Annex 2 for antibiotic intermediate manufacturing
• FDA Q7A API production requirements specifically applied to beta-lactam intermediates
• CEP (Certificate of Suitability to the Monographs of the European Pharmacopoeia) procedures for antibiotic APIs

Typical usage ratio

• 0.9–1.1 equivalents per beta-lactamase core unit, optimized based on specific inhibitor structure and side-chain requirements

Downstream process integration

• Employed at the lactam ring closure stage or as a resolved intermediate, followed by Boc removal and further N-alkylation

Final product types

• Oral and injectable beta-lactamase inhibitor drugs (e.g., avibactam derivatives)
• Combination antibiotic formulations for hospital use
• Bulk intermediates supplied to generic antibiotic API factories

5. Protected Intermediate for Custom Oligopeptide Synthesis in Research and Diagnostics

Academic and biotech laboratories utilize this compound in synthesizing modified oligopeptides for use in molecular biology assays, diagnostic reagents, and biomarker identification. The stereochemical purity and selectable Boc protection provide flexible options for producing both standard and custom-labeled peptides, supporting high-throughput screening and protein–protein interaction studies.

Industry compliance standards

• ISO 13485:2016 Quality Management Systems for diagnostic manufacturers
• Good Laboratory Practice (GLP) requirements for research reagents
• OECD Principles of Good Laboratory Practice

Typical usage ratio

• 0.2–1.0 equivalents per peptide or oligo backbone position, scaled to synthetic length and label incorporation strategy

Downstream process integration

• Added during custom peptide assembly on automated synthesizers; Boc group removed post-assembly for reactive labeling or modification

Final product types

• Peptide antigens for immunoassay development
• Custom-labeled peptides for bioanalytical applications
• Research-use-only oligopeptides with reporter tags